Abstract

ASSESS THE WEIGHT NEUTRALITY EFFECT OF METFORMIN IN TYPE-II DIABETIC PATIENTS AT TERTIARY CARE HOSPITAL

T. Aravinth*, R. Sivasakthi and J. Girithara Gopalakrishnan

ABSTRACT

Introduction: Metformin is a First line drug for the effective management of type 2 diabetes mellitus. The monotherapy of metformin is well tolerated, Cost effective and less adverse drug reaction. The Combination therapy also safe and effective in glycaemic control. It is a evidence based drug with benefits of glycaemic control, weight reduction and less cardiovascular disease. The major mechanism of metformin is inhibition of hepatic gluconeogenesis Previous studies indicates that, Diabetes patient with Overweight and Obesity can be managed by administration of Metformin. Aim: The study assesses the weight neutrality effect of Metformin in Type-II diabetic patients. Methodology: The Prospective, observational, Comparative study was Conducted with 120 patients for the Period of 6 months at KG Hospital. Coimbatore. Data were collected and analysed with SPSS software. Result: The total of 150 study population, 62% (n=93) were Male and 38% (n=57) were female. The study indicates the average weight of patients in group A from baseline to 6th month was 65.52, 64.15, 63.86, 63.12 respectively. The average weight of patients in group B from baseline to 6th month was 64.75, 66.32, 65.70, 66.12 respectively. Conclusion: The study concludes that, Metformin has safe and effective first line drug for Type-II diabetic patients. It has weight neutrality effect. Hence, it can be prescribed for Type-II diabetes patients with Obesity.

Keywords: Metformin, Monotherapy, Type-II diabetics, Weight neutrality.